Abstract
The effects of a chronic treatment with corticosteroids on bone are well known, but few data are available regarding the acute effect of these drugs on bone turnover. This study was aimed at evaluating the effects of high doses of corticosteroids administered for a short period on bone metabolism. We assessed 23 subjects (15 women and 8 men) suffering from multiple sclerosis and treated with methylprednisolone (1 g iv for 10 days) followed by oral prednisone for 9 days; patients affected by diseases involving bone or treated during the previous 6 months with drugs influencing bone metabolism were excluded. We observed a significant decrease of ALP and bone glia protein (BGP), in these subjects, and a significant sudden increase of urinary calcium/creatinine and urinary cross-laps after 3 days of treatment. All of these parameters, except urinary calcium/creatinine, returned to basal levels after 30 days from the beginning of treatment (11 days after the interruption of corticosteroids administration). Serum phosphorus showed a significant decrease after 3 days of treatment, but returned to basal levels after 10 days. These data suggest that high doses of corticosteroids administered for a short period are able to induce an increase of bone resorption and a decrease of bone formation; moreover, bone turnover returns to basal levels when the treatment is stopped.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Int. Med. 1990, 112: 352–364.
Lo Cascio V., Bonucci E., Imbimbo B., et al. Bone loss in response to long-term glucocorticoid therapy. Bone Min. 1990, 8: 39–51.
Reid I.R. Glucocorticoid osteoporosis — mechanisms and management. Eur. J. Endocrinol. 1997, 137: 209–217.
Eastell R., Reid D.M., Compston J., et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J. Intern. Med. 1998, 244: 271–292.
Adachi J.D. Corticosteroid-induced osteoporosis. Am. J. Med. Sci. 1997, 313: 41–49.
Adinoff A.D., Hollister J.R. Steroid induced fractures and bone loss in patients with asthma. N. Engl. J. Med. 1983, 309: 265–268.
Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid induced osteoporosis. J. Clin. Endocrinol. Metab. 1996, 81: 3441–3447.
Godschalk M.F., Downs R.W. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. Bone Min. Res. 1988, 3: 113–115.
Gennari C., Bernini M., Nardi P., et al. Hormones and the intestinal absorption of calcium and phosphate in man. Hormone Res. 1984, 20: 13–21.
Gennari C., Imbimbo B., Montagnani M., et al. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif. Tissue Int. 1984, 36: 245–252.
Reid I.R., Ibberstone H.K., France J.T., Pybus J. Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. Br. Med. J. 1985, 291: 574.
Reid I.R. Pathogenesis and treatment of steroid osteoporosis. Clin. Endocrinol. (Oxf.) 1989, 30: 83–103.
Monolagas S.C. Corticosteroids and fractures: a close encounter of the third cell kind. J. Bone Min. Res. 2000, 15: 1001–1005.
Saag K.G., Emkey K., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 1998, 339: 292–299.
Reid D.M., Hughes A., Laan R., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J. Bone Min. Res. 2000, 15: 1006–1013.
Luengo M., Picado C., Del Rio L., et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991, 46: 803–806.
Schwid S.R., Goodman A.D., Puzas J.E., McDermott M.P., Mattson D.H. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch. Neurol. 1996, 53: 753–757.
Cosman F., Nieves J., Herbert J., Shen V., Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J. Bone Min. Res. 1994, 9: 1097–1105.
Minisola S., Pacitti M., Paglia F., et al. Biomarkers of bone turnover following a short period of steroid therapy in elderly men. J. Bone Min. Res. 2000, 15: 543 (Abstract).
Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1993, 33: 1444–1452.
Cosman F., Nieves J., Komar L., et al. Fracture history and bone loss in patients with MS. Neurology 1998, 51: 1161–1165.
Nieves J., Cosman F., Herbert J., Shen V., Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994, 44: 1687–1692.
Tuzun S., Altintas A., Karacan I., Tangurek S., Siva A. Multiple sclerosis; the role of corticosteroids and immobility on bone mineral metabolism. Osteoporosis International 2000, 11 (Abstract): 86.
Lems W.F., Gerrits M.I., Jacobs J.W., et al. Changes in markers of bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1996, 55: 288–293.
Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanism of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140: 4382–4389.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ardissone, P., Rota, E., Durelli, L. et al. Effects of high doses of corticosteroids on bone metabolism. J Endocrinol Invest 25, 129–133 (2002). https://doi.org/10.1007/BF03343976
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343976